Delivery Order SPE2DB22D2206-SPE2DB25FGD02

Award Date 3/17/25
Potential Completion Date 4/7/25
Potential Value $178K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm-fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award valued at $178,310.12 from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REVLIMID 10 MG CAPSULE 100S, a prescription medication. The contract is a firm fixed-price agreement with a period of performance through January 24, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,281.49, is for the delivery of REVLIMID 25 MG CAPSULE 21S, a pharmaceutical product. The contract has an ultimate completion date of January 23, 2024 and is a Firm Fixed Price contract. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract, valued at $27,859.78, is for the delivery of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product, with a performance period through April 3, 2024. This delivery order is issued under an indefinite delivery contract (IDC) previously awarded to Amerisourcebergen Drug Corp...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 10 MG CAPSULE 28S. The contract has a ceiling value of $212,188.94 and an ultimate completion date of September 24, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which serves as a primary vehicle for AmerisourceBergen to provide a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,890.20, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of January 24, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,963.40 firm fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of March 11, 2025 and was awarded on February 18, 2025. This appears to be a task order under a larger Indefinite Delivery Contract (IDC) that...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $49,926.80, is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of March 20, 2025 and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
The Defense Logistics Agency (DLA) awarded a $99,853.60 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp for the supply of REVLIMID 10 MG CAPSULE 28S. This contract has an ultimate completion date of August 19, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies to provide a wide range of essential medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The $56,490.52 firm-fixed-price contract is for the delivery of Revlimid 10 mg capsules and has an ultimate completion date of January 22, 2024. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FGD02
    Delivery Order

This is a firm-fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is for the supply of REVLIMID 5 MG CAPSULE 100S, a medical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. This contract award demonstrates AmerisourceBergen's critical role in supplying essential medical products to federal government agencies, particularly the Department of Defense and its military healthcare system.

Generated 6/16/25, 10:54 AM